MTOR and non-small cell lung carcinoma: As mentioned before, EGFR-TKIs can inhibit PD-L1 expression in NSCLC with mutant EGFR, and the AKT/mTOR pathway has been validated as responsible for EGFR-mediated PD-L1 expression [40].